GPP
KPTI icon

Great Point Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Great Point Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,000
Closed -$3.49M – 42
2014
Q2 		$3.49M Buy
+5,000
New +$2.33M 1.55% 22

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's KPTI Position: Q3 2014 in Review

Great Point Partners sold out of Karyopharm Therapeutics (KPTI) in Q3 2014, closing a stake of 5,000 shares — an estimated $3.49M sold.

Great Point Partners first reported a position in KPTI in Q2 2014 and held it in 1 quarter. The position peaked at $3.49M in Q2 2014. 71 funds tracked by Wall St. Rank hold KPTI as of Q3 2014.

  • Great Point Partners reported no remaining Karyopharm Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Great Point Partners sold 5,000 Karyopharm Therapeutics shares in Q3 2014, an estimated $3.49M.
  • Great Point Partners first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 1 quarter.
  • Great Point Partners's Karyopharm Therapeutics position peaked at $3.49M in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2014.

Based on Great Point Partners's 13F filing for Q3 2014, filed 14 Nov 2014.